• From Curious Learner to Pioneer: Dr. Jie Chen’s Medical Evolution

    As we step further into the 21st century, the field of medicine has undergone tremendous changes. Among the many advancements, a generation of compassionate and skilled doctors has emerged, dedicated to the wellbeing of their patients and their nation. The phrase “a doctor’s heart is like a parent’s” perfectly captures this essence. In the Oncology…

  • Serum Albumin as a Prognostic Factor in Acute Myeloid Leukemia

    In June 2024, Blood Science published a pivotal study led by Dr. Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , investigating the prognostic significance of serum albumin levels in patients with acute myeloid leukemia (AML). AML is a highly aggressive hematological…

  • Plerixafor-Based Mobilization and Increased Mononuclear Cell Counts: Risk Factors for Engraftment Syndrome Post-Autologous Hematopoietic

    In June 2024, Blood Science published a significant study led by Dr. Xiaohui Zhang and colleagues from the Peking University People’s Hospital, focusing on the incidence and risk factors of engraftment syndrome (ES) following autologous hematopoietic stem cell transplantation (ASCT) in the era of plerixafor-based mobilization. ASCT remains a critical therapy for hematologic malignancies, particularly…

  • 2024 Nobel Prize | MicroRNAs (miRNAs) and Liver Diseases

    RNAs serve diverse functions, with one of the key roles being to guide protein synthesis, which is fundamental to life. MicroRNAs are a class of endogenous non-coding RNAs that play…

  • New Characteristics of BL/BLI Compounds Targeting Non-KPC Enterobacterales

    Background The rise of carbapenem-resistant Gram-negative organisms (CRO) poses a significant public health challenge, prompting researchers to focus on developing new antimicrobial agents and enhancing infection control and antimicrobial stewardship…

  • Ivosidenib in Chinese Patients with Relapsed or Refractory IDH1-Mutated Acute Myeloid Leukemia: A Registry Study

    In June 2024, Blood Science published an important study led by Dr. Jie Jin and colleagues from the The First Affiliated Hospital, Zhejiang University School of Medicine, investigating the safety, pharmacokinetics, and efficacy of ivosidenib in Chinese patients with relapsed or refractory (R/R) isocitrate dehydrogenase 1 (IDH1)-mutated acute myeloid leukemia (AML). AML, a heterogeneous and…

  • Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

    In April 2024, the journal Blood Science published an important study led by Dr. Gang An and colleagues from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigating the use of subcutaneous daratumumab in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). Multiple myeloma is…

  • Targeting HMGCS1 Restores Chemotherapy Sensitivity in Acute Myeloid Leukemia

    In June 2024, Blood Science published a groundbreaking study led by Dr. Hui Zeng and colleagues from the The First Affiliated Hospital of Jinan University , focusing on the role of 3-hydroxy-3-methylglutaryl coenzyme A synthase 1 (HMGCS1) in acute myeloid leukemia (AML). AML is a severe hematological malignancy characterized by the rapid proliferation of immature…